What Is Retinitis Pigmentosa?
Retinitis Pigmentosa (RP) is a large group of degenerative eye conditions that cause progressive deterioration of the retina — specifically, the photoreceptor cells (rods and cones) that convert light into visual signals. It is one of the most common causes of blindness in people of working age, affecting approximately 1 in 3,500–5,000 people worldwide. RP is a genetically diverse condition — over 90 genes have been identified as causative, meaning there are many different underlying molecular mechanisms. It is most commonly degenerative as autosomal dominant, autosomal recessive, or X-linked recessive. The condition typically begins with loss of rod photoreceptors (responsible for night and peripheral vision) before cones (responsible for central and colour vision) are affected.
Common Symptoms
RP typically presents in adolescence or early adulthood, though the age of onset and rate of progression vary widely. Common symptoms include: difficulty seeing in low light or darkness (night blindness / nyctalopia) — often the earliest symptom; progressive narrowing of the visual field (tunnel vision) — peripheral vision is lost before central vision; light sensitivity (photophobia) — patients may struggle in bright sunlight; progressive reduction in central visual acuity as the condition advances; reduced colour vision; glare sensitivity; and in later stages, significant vision loss including legal blindness. The rate of progression varies significantly — some individuals retain useful vision into their 50s or 60s, while others experience rapid vision loss in early adulthood.
Research & Treatment Development
RP research has accelerated dramatically in recent years. Active areas include: targeted molecular studies — the first FDA-approved targeted molecular therapy for RP (voretigene neparvovec-rzyl / Luxturna) treats RPE65-associated RP; AAV-based targeted molecular therapy for other RP subtypes is in active clinical trials; advanced medical innovation approaches targeting retinal photoreceptor regeneration; retinal prostheses and visual implants including the Argus II and Orion devices; optogenetic approaches using light-sensitive proteins introduced into surviving retinal cells; cell-based therapies exploring advanced laboratory-derived RPE and photoreceptor cell support approaches; pharmacological neuroprotection using neurotrophic factors; and early detection and monitoring tools including full-field electroretinography (ERG) and adaptive optics imaging.
Our Approach at Med Cure Centre
Med Cure Centre provides specialist care for Retinitis Pigmentosa patients at all stages of the condition. Our ophthalmology team, led by Dr. Pallavee R. Goswami (Consultant Ophthalmologist, 26 Years Experience), conducts comprehensive genetic and clinical assessment including ERG, visual field testing, and OCT imaging. We develop personalised treatment protocols based on genetic subtype, disease stage, and visual function. We are transparent about what current treatment can achieve and are committed to keeping patients informed of the latest developments in RP research. We support patients from over 50 countries with online consultation and remote follow-up services.
📄 Scientific References
- National Institutes of Health (NIH) — National Library of Medicine. PubMed database. pubmed.ncbi.nlm.nih.gov
- World Health Organization (WHO) — Neurological Disorders & Eye Health Resources. who.int
- American Academy of Ophthalmology / Neurology — Clinical guidelines and disease statistics. aao.org